Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeneFIX in Children < 6 Years with Severe Hemophilia B
NCT00037557Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Pfizer. Started Sep 2002; status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT00037557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00037557.